Free Trial

Keudell Morrison Wealth Management Invests $334,000 in Kymera Therapeutics, Inc. $KYMR

Kymera Therapeutics logo with Medical background

Key Points

  • Keudell Morrison Wealth Management has invested $334,000 in Kymera Therapeutics by purchasing 7,660 shares in the second quarter.
  • Kymera Therapeutics stock has recently seen a 3.4% increase, and analysts have mixed ratings, with a consensus rating of "Moderate Buy" and an average price target of $61.26.
  • In the most recent quarter, Kymera reported earnings of ($0.95) per share, falling short of analysts' estimates, with revenue of $11.48 million, down 55.1% year-over-year.
  • MarketBeat previews top five stocks to own in November.

Keudell Morrison Wealth Management purchased a new stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 7,660 shares of the company's stock, valued at approximately $334,000.

Other institutional investors have also made changes to their positions in the company. Farther Finance Advisors LLC boosted its stake in shares of Kymera Therapeutics by 642.9% in the second quarter. Farther Finance Advisors LLC now owns 624 shares of the company's stock valued at $27,000 after buying an additional 540 shares during the period. Caitong International Asset Management Co. Ltd bought a new stake in shares of Kymera Therapeutics in the first quarter valued at approximately $68,000. KBC Group NV boosted its stake in shares of Kymera Therapeutics by 15.2% in the first quarter. KBC Group NV now owns 2,479 shares of the company's stock valued at $68,000 after buying an additional 328 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Kymera Therapeutics by 15.8% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,516 shares of the company's stock valued at $110,000 after buying an additional 343 shares during the period. Finally, Advisors Asset Management Inc. boosted its stake in shares of Kymera Therapeutics by 81.7% in the first quarter. Advisors Asset Management Inc. now owns 4,959 shares of the company's stock valued at $136,000 after buying an additional 2,230 shares during the period.

Kymera Therapeutics Stock Up 3.4%

NASDAQ KYMR opened at $57.90 on Friday. The company has a market capitalization of $4.14 billion, a price-to-earnings ratio of -16.69 and a beta of 2.26. Kymera Therapeutics, Inc. has a twelve month low of $19.44 and a twelve month high of $59.00. The stock has a fifty day simple moving average of $45.67 and a 200 day simple moving average of $39.39.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last posted its quarterly earnings data on Monday, August 11th. The company reported ($0.95) earnings per share for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.12). The company had revenue of $11.48 million during the quarter, compared to analyst estimates of $17.37 million. Kymera Therapeutics had a negative net margin of 616.03% and a negative return on equity of 31.60%. The business's revenue for the quarter was down 55.1% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.58) earnings per share. Research analysts expect that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently issued reports on KYMR shares. Wells Fargo & Company cut their price target on Kymera Therapeutics from $57.00 to $53.00 and set an "overweight" rating for the company in a research note on Thursday, June 26th. Jefferies Financial Group set a $64.00 price target on Kymera Therapeutics and gave the company a "buy" rating in a research note on Wednesday, June 25th. The Goldman Sachs Group upgraded shares of Kymera Therapeutics to a "strong-buy" rating in a research report on Tuesday, July 15th. BTIG Research restated a "buy" rating and set a $59.00 price objective on shares of Kymera Therapeutics in a research report on Thursday, June 26th. Finally, B. Riley upgraded shares of Kymera Therapeutics to a "strong-buy" rating and set a $60.00 price objective for the company in a research report on Wednesday, July 30th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $61.26.

Read Our Latest Report on Kymera Therapeutics

Insiders Place Their Bets

In related news, CFO Bruce N. Jacobs sold 79,220 shares of the stock in a transaction on Wednesday, September 17th. The stock was sold at an average price of $50.00, for a total value of $3,961,000.00. Following the completion of the sale, the chief financial officer directly owned 227,409 shares in the company, valued at $11,370,450. This represents a 25.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Nello Mainolfi sold 30,000 shares of the company's stock in a transaction on Tuesday, September 16th. The shares were sold at an average price of $49.00, for a total transaction of $1,470,000.00. Following the sale, the chief executive officer directly owned 660,482 shares in the company, valued at $32,363,618. This trade represents a 4.34% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 16.01% of the company's stock.

About Kymera Therapeutics

(Free Report)

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.

Further Reading

Institutional Ownership by Quarter for Kymera Therapeutics (NASDAQ:KYMR)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Kymera Therapeutics Right Now?

Before you consider Kymera Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kymera Therapeutics wasn't on the list.

While Kymera Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report
Like this article? Share it with a colleague.